The Maudsley Prescribing Guidelines in Psychiatry
Author(s): Dr. David Taylor
Helps with complex prescribing needs
The evidence base for drug treatments in psychiatry ranges frommeta-analyses and randomised controlled clinical trials tosingle case reports, and from NICE guidelines to individualSPCs. Where do you look for information when transferring apatient from one drug to another? Where do you find a clearoverview when dealing with a complex patient (e.g, with co-morbidepilepsy or liver disease or HIV infection)? Where canyou seek advice on prescribing psychotropics duringpregnancy? The Maudsley Prescribing Guidelines inPsychiatry! The leading clinical reference for handlingprescribing problems as encountered in daily practice and forformulating prescribing policy.
Evidence-based and written by experts
This book is the essential guide for anyone responsible forprescribing, dispensing or administering drugs for patients withmental health disorders. All the evidence has been reviewedand summarized succinctly by an expert team of psychiatrists andpharmacists.
New content and improved format
This new edition makes greater use of tables and boxes tofacilitate quick reference and includes new sections oncytochrome-mediated interactions and psychiatric side effects ofnon-psychotropic drugs.
Clinically relevant
Chapters address plasma monitoring, schizophrenia, bipolardisorder, depression and anxiety, children and adolescents,substance abuse and special patient groups. Each section hasa full reference list. The book covers prescribing drugsoutside their licensed indications and their interaction withsubstances such as alcohol, nicotine and caffeine.
Useful for all levels of experience
Trainees will gain important information regarding the rational,safe and effective use of medications for patients with mentalillness. Experienced clinicians will find excellent guidanceregarding more complex issues that they may not encounterregularly.
Why the Maudsley Prescribing Guidelines inPsychiatry?
Long recognized as an international trailblazer in mental healthcare, the Maudsley Hospital earned its reputation for excellence inboth in-patient and community care.
It is highly regarded forits research, and pioneered the use of clinical neuroscience. Youcan trust The Maudsley Prescribing Guidelines in Psychiatryto be scientifically sound and clinically effective.
Product Information
David Taylor is Director of Pharmacy and Pathology at theSouth London and Maudsley NHS Foundation Trust, and Professor ofPsychopharmacology at King s College London. The leadauthor of all editions of the Maudsley PrescribingGuidelines, Professor Taylor is the author of several othertexts and editor of Therapeutic Advances inPsychopharmacology.
Carol Paton is Chief Pharmacist at Oxleas NHS FoundationTrust, London: she is also joint Head of the PrescribingObservatory for Mental Health and an Honorary Research Fellow atImperial College London.
Shitij Kapur is Professor of Schizophrenia, Imaging andTherapeutics and the Dean and Head of School at the Institute ofPsychiatry, King's College London.
Preface ix
Acknowledgements x
Notes on using The Maudsley Prescribing Guidelines xi
Notes on inclusion of drugs xi
List of abbreviations xii
Chapter 1 Plasma level monitoring of psychotropic drugs andanticonvulsants 1
Interpreting sample results 2
Chapter 2 Schizophrenia 11
Antipsychotic drugs 11
Antipsychotic drugs: equivalent doses 13
Antipsychotic drugs: minimum effective doses 14
Antipsychotic drugs: licensed maximum doses 16
New antipsychotic drugs 17
Antipsychotic drugs: general principles of prescribing 21
National Institute for Health and Clinical Excellence guidelinesfor the treatment of schizophrenia 22
Treatment algorithms for schizophrenia 24
Antipsychotic drugs: monitoring of metabolic effects 26
Switching antipsychotic drugs because of poor tolerability31
Antipsychotic response: to increase the dose, to switch, to addor just wait what is the right move? 33
Speed and onset of antipsychotic drug action 36
First-generation antipsychotic drugs: place in therapy 39
Antipsychotic drugs: long-acting injections 40
Risperidone long-acting injection 44
Paliperidone palmitate long-acting injection 47
Management of patients on long-term depots: dose reduction50
Combined antipsychotic drugs 51
High-dose antipsychotic drugs: prescribing and monitoring 54
Negative symptoms in schizophrenia 57
Antipsychotic prophylaxis 60
Refractory schizophrenia and clozapine 64
Clozapine augmentation 66
Refractory schizophrenia: alternatives to clozapine 69
Clozapine: management of common adverse effects 75
Clozapine: uncommon or unusual adverse effects 78
Clozapine: serious haematological and cardiovascular adverseeffects 80
Clozapine, neutropenia and lithium 84
Clozapine and chemotherapy 88
Clozapine-related hypersalivation 89
Guidelines for the initiation of clozapine for patients based inthe community 92
Omega-3 fatty acids (fish oils) in schizophrenia 96
Extrapyramidal side-effects of antipsychotic drug treatment98
Treatment of antipsychotic-induced akathisia 103
Treatment of tardive dyskinesia 105
Neuroleptic malignant syndrome 110
Catatonia 113
Cardiovascular effects of antipsychotic drug treatment 115
Antipsychotic drugs and hypertension 122
Hyperprolactinaemia 123
Antipsychotic-induced weight gain 126
Treatment of drug-induced weight gain 128
Antipsychotic drugs, diabetes and impaired glucose tolerance132
Antipsychotic drugs and dyslipidaemia 138
Antipsychotic drugs and sexual dysfunction 142
Antipsychotic-associated hyponatraemia 148
Antipsychotics and pneumonia 150
Relative adverse effects of antipsychotic drugs: a rough guide151
Chapter 3 Bipolar disorder 153
Valproate 153
Lithium 159
Carbamazepine 168
Physical monitoring of people with bipolar disorder 173
Treatment of acute mania or hypomania 176
Antipsychotic drugs in bipolar disorder 182
Bipolar depression 185
Rapid cycling bipolar disorder 191
Prophylaxis in bipolar disorder 193
Chapter 4 Depression and anxiety 197
Depression 197
Antidepressants 201
Treatment of resistant depression 222
Treatment of psychotic depression 233
Electroconvulsive therapy and psychotropic drugs 235
Psychostimulants in depression 239
Treatment of depression in the elderly 243
Treatment of depression in stroke 247
Adverse effects of antidepressants 249
Selective serotonin reuptake inhibitors and bleeding 252
Depression and diabetes 255
Cardiac effects of antidepressants 257
Antidepressants and sexual dysfunction 264
Antidepressants and hyperprolactinaemia 268
Antidepressants: swapping and stopping 270
St John s wort in the treatment of depression 278
Drug interactions with antidepressants 281
Alternative routes of administration for antidepressants 286
Anxiety spectrum disorders 292
Benzodiazepines in the treatment of psychiatric disorders301
Benzodiazepines and disinhibition 304
Benzodiazepines: dependence and detoxification 306
Insomnia 310
Chapter 5 Children and adolescents 315
Principles of prescribing practice in childhood and adolescence315
Depression in children and adolescents 316
Bipolar illness in children and adolescents 321
Psychosis in children and adolescents 326
Anxiety in children and adolescents 327
Obsessive compulsive disorder in children and adolescents328
Attention deficit hyperactivity disorder 332
Autism spectrum disorders 337
Tics and Tourette s syndrome 345
Melatonin in the treatment of insomnia in children andadolescents 349
Rapid tranquillisation in children and adolescents 351
Doses of commonly used psychotropic drugs in children andadolescents 354
Chapter 6 Substance misuse 355
Alcohol dependence 356
Opioid misuse and dependence 372
Nicotine and smoking cessation 398
Stimulant drugs of dependence 406
Benzodiazepine misuse 407
-Butaryl-lactone and -hydroxybutyrate dependence 408
Drugs of misuse: a summary 410
Interactions between street drugs and prescribedpsychotropic drugs 414
Chapter 7 Use of psychotropic drugs in special patient groups419
Epilepsy 419
Pregnancy 430
Breast feeding 446
Renal impairment 462
Hepatic impairment 478
Prescribing in the elderly 487
Dementia 490
Behavioural and psychological symptoms of dementia 509
Parkinson s disease 518
Multiple sclerosis 522
Eating disorders 527
Acutely disturbed or violent behaviour 531
Psychotropic medications for adults with learning disabilities539
Borderline personality disorder 545
Delirium 547
Huntington s disease 554
Psychotropic drugs and surgery 558
Prescribing psychotropic drugs for patients with HIV infection564
Psychotropic drugs and cytochrome (CYP) function 573
Summary of psychiatric side-effects of non-psychotropic drugs578
Chapter 8 Miscellaneous conditions and substances 587
Psychotropic drugs in overdose 587
Biochemical and haematological effects of psychotropic drugs593
Prescribing drugs outside their licensed indications 604
Observations on the placebo effect in mental illness 606
Drug interactions with alcohol 608
Nicotine 613
Smoking and psychotropic drugs 616
Caffeine 618
Complementary therapies 624
Enhancing medication adherence 628
Driving and psychotropic medicines 634
Covert administration of medicines within food and drink 643
Index 647
General Fields
- :
- : John Wiley and Sons Ltd
- : Wiley-Blackwell
- : 1.016
- : 01 March 2012
- : 219mm X 175mm X 27mm
- : United States
- : books
Special Fields
- : Illustrations
- : Illustrations
- : 680
- : 615.1
- : 11th Revised edition
- : Paperback
- : Dr. David Taylor